{
    "nct_id": "NCT06386146",
    "official_title": "A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation",
    "inclusion_criteria": "* Written informed consent.\n* Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).\n* ECOG performance status score of 0 or 1.\n* Has been treated with at least one line of systemic therapy for that tumor type and stage.\n* Have documentation of confirmed TP53 Y220C mutation.\n* At least 1 measurable lesion per RECIST v1.1.\n* Adequate hematological, renal and hepatic function and appropriate coagulation condition.\n* Able to swallow and retain orally administered medication.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain or spinal metastases or primary CNS tumor.\n* Active infection requiring systemic treatment within 7 days.\n* Active HBV or HCV.\n* Any severe and/or uncontrolled medical conditions.\n* LVEF ≤50% assessed by ECHO or MUGA.\n* QTcF>470 msec.",
    "miscellaneous_criteria": ""
}